Clinical trials
catalyst calendar across sponsors →Studies where CTNM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 with posted results
Held by 12 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, HHLR ADVISORS, LTD., CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, +7 more) · FINRA short interest 13.5 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisNCT07284459Absolute change in forced vital capacity (FVC) (mL)Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: PIPE-791 Dose A, PIPE-791 Dose B, Placebo | Idiopathic Pulmonary Fibrosis | 324 | May 2028 | ≤ 651 d | 2026-08-19 |
| Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back PainNCT06810245Number of subjects with Treatment-emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: PIPE-791, Placebo | Chronic Osteoarthritis Pain, Chronic Low Back Pain | 43 | 2026-01-20actual | — | 2026-03-18 |
| PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFNCT06683612LPA1 occupancy as determined by regional total volume of distribution (VT) at each brain scan.Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PIPE-791 | Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Progressive, Multiple Sclerosis, Secondary Progressive, Healthy, Healthy Volunteers | 16 | 2025-06-04actual | — | 2025-08-06 |
| Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy VolunteersNCT05983939Safety: Treatment-Emergent Adverse Events (TEAE)Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: PIPE-791, Placebo | Multiple Sclerosis | 56 | 2024-02-01actual | — | 2024-02-14 |
| PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy VolunteersNCT04941781M1AChR receptor occupancy as determined by regional total volume of distribution (VT) of [11C] PIPE-307 at 24 hoursOpen-label · Treatment | Phase 1 | Completed | Drug: PIPE-307 | Multiple Sclerosis | 6 | 2021-11-10actual | — | 2022-10-05 |
| Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy VolunteersNCT04725175Safety: Treatment-Emergent Adverse Events (TEAE)Randomized · Double-masked · Treatment | Phase 1 | Completed | Drug: PIPE-307, Placebo oral tablet | Multiple Sclerosis | 70 | 2021-09-01actual | — | 2021-11-03 |
| Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing LossNCT04462198results2025-03-04Safety: Treatment-Emergent Adverse Events (TEAE)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: PIPE-505, Placebo | Sensorineural Hearing Loss | 28 | 2021-06-17actual | — | 2025-04-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19